OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

ModifiedHealthfirstPolicy PO-RE-018v8

Diagnosis of Vaginitis

Customize your policy alerts

Sign up for Healthfirst Policy PO-RE-018v8 alerts

Get alerted when Policy PO-RE-018v8 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Coverage and clinical guidance for laboratory and point-of-care testing to diagnose causes of vaginitis (BV, vulvovaginal candidiasis, and trichomoniasis) for symptomatic individuals; describes which tests meet or do not meet coverage criteria.

Policy Summary

PayerHealthfirst

PolicyDiagnosis of Vaginitis

Policy CodePolicy PO-RE-018v8

Change TypeMaterial revisions and coding updates

Effective DateFeb 1, 2026

Last ReviewDec 15, 2025

Next Review DateN/A

Key ActionOrder NAAT panels only for symptomatic patients and limit repeat panel testing to no more than one test every 7 days; document symptoms and initial office test findings when ordering.

SourceLink

POLICY UPDATE CHANGES

Individual organism testing for T. vaginalis moved to G2157 and results in removal of CC4, CC5, and CC10.

Added 'qualitative' to define the correct type of NAAT testing to be used to screen for Candida infection for complicated VVC.

NAAT panel testing for vaginitis limited to no more than one test every seven days (Note 1) and should not be repeated before a minimum treatment window has passed.

New coverage statement: quantitative NAAT testing for Candida DOES NOT MEET COVERAGE CRITERIA in situations not otherwise described.

Added CPT code 0068U and CPT code 0557U (effective 7/1/2025); removed CPT codes 87661 and 87808 and earlier-specified codes per off-cycle modifications.

5+molecular NAAT/DNA assays named or summarized

7 daysNAAT panel retest interval

meetsoffice diagnostic methods meeting coverage

not coveredscreening asymptomatic individuals

0068U/0557UCPT additions/removals noted

Coverage Criteria for Testing of Vaginitis

Office and basic laboratory diagnostic methods

Covered when ALL of the following are met for symptomatic individuals:

Initial diagnostic tests: Measurement of vaginal pH, amine (whiff) testing, measurement of sialidase activity, saline wet mount, potassium hydroxide (KOH) wet mount, and microscopic examination of vaginal fluids

These meet coverage criteria for individuals with signs and symptoms of vaginitis.

Molecular and NAAT testing

Covered molecular and NAAT tests for symptomatic individuals:

Targeted molecular tests: Direct probe DNA-based identification of Gardnerella, Trichomonas, and Candida (e.g., BD Affirm VPIII) meets coverage criteria.

Cultures for Candida:

Policy Summary

PayerHealthfirst

PolicyDiagnosis of Vaginitis

Policy CodePolicy PO-RE-018v8

Change TypeMaterial revisions and coding updates

Effective DateFeb 1, 2026

Last ReviewDec 15, 2025

Next Review DateN/A

Key ActionOrder NAAT panels only for symptomatic patients and limit repeat panel testing to no more than one test every 7 days; document symptoms and initial office test findings when ordering.

SourceLink

On This Page

Vaginal cultures for Candida species meet coverage criteria when clinical signs and symptoms are present but wet mount and pH are negative.

PCR for complicated VVC: Qualitative PCR-based identification of Candida to confirm diagnosis and identify non-albicans species in complicated vulvovaginal candidiasis meets coverage criteria.qualitative NAAT

NAAT specific for BV: NAAT specific to bacterial vaginosis (e.g., Aptima BV; OneSwab BV Panel; SureSwab Advanced BV, TMA) meets coverage criteria for individuals with signs and symptoms of BV.

NAAT multi-target panels: NAAT panel testing designed to detect more than one type of vaginitis (VVC, BV, and/or trichomoniasis) meets coverage criteria when used for symptomatic individuals; limited to one test every 7 days.no more than one test every 7 days

See Note 1 regarding treatment window and repeat testing.

Molecular NAAT testing for symptomatic vaginitis

Covered when ALL of the following are met

Symptomatic indication: Patient has signs or symptoms of vaginitis (e.g., abnormal vaginal discharge, odor, itch, or vulvar irritation)

CDC and clinical studies recommend use of NAATs for symptomatic women only.

Diagnostic rationale documented: Clinical evaluation (history and physical) and relevant office tests (vaginal pH, KOH whiff test, wet-mount microscopy) are performed or documentation that microscopy is unavailable

CDC: if microscopy unavailable, molecular tests appropriate; document findings to support testing.

Test selection: Selection of an FDA-cleared or validated molecular assay (for example, BD MAX Vaginal Panel, Aptima BV/CV/TV, Xpert Xpress MVP) appropriate to detect BV, Candida species, and Trichomonas vaginalis

Use assays validated for symptomatic vaginitis; platforms differ in targets and interpretation algorithms.

Medical necessity criteria for diagnostic testing

Covered diagnostic testing for vaginitis when aligned with guideline-recommended indications and symptomatic presentation.

Symptomatic testing: Diagnostic testing (microscopy, Amsel criteria, Gram stain with Nugent scoring, culture, or multiplex NAATs) is appropriate when the patient has signs or symptoms consistent with vaginitis (e.g., abnormal discharge, pruritus, malodor, vulvar irritation)

IDSA and ACOG recommend diagnostic confirmation for VVC and BV; multiplex NAATs are intended for symptomatic patients and not for screening.

Test selection: Use Amsel criteria or Gram stain with Nugent scoring for BV and wet-mount microscopy or culture to confirm VVC when microscopy is inconclusive; multiplex NAATs may be used as an alternative and can detect coinfections with higher sensitivity

ACOG recommends Amsel/Nugent for BV and microscopy/culture for VVC; NAATs offer higher sensitivity and identify coinfections.

Pregnancy considerations: Do not screen asymptomatic pregnant persons for BV unless at increased risk for preterm delivery; symptomatic pregnant patients should be tested and treated per relevant guidelines

USPSTF recommends against routine screening in low-risk pregnancy; SOGC and CDC provide guidance for symptomatic pregnant patients.

Revised Coverage Statements (selected)

Selected coverage clarifications from Revision History

NAAT panel retesting window: For individuals with signs and symptoms of vaginitis, NAAT panel testing designed to detect more than one type of vaginitis (VVC, BV, and/or trichomoniasis) MEETS COVERAGE CRITERIA but is limited to no more than one test every seven days; panels should not be repeated before the minimum treatment window has passed.no more than one test every 7 days

See Note 1 in revision history; when symptoms persist despite treatment, individual organism testing may be performed within this window.

Complicated VVC testing: For individuals with complicated vulvovaginal candidiasis (VVC), qualitative PCR-based identification of Candida to confirm clinical diagnosis and identify non-albicans Candida MEETS COVERAGE CRITERIA.qualitative NAAT

Former CC6 now CC4 updated to add 'qualitative'.

Quantitative Candida NAAT: For all other situations not described above, NAAT testing for Candida (for example, quantitative NAAT testing) DOES NOT MEET COVERAGE CRITERIA.quantitative NAAT excluded unless earlier criteria met

New CC8 added in revision history clarifies exclusion of quantitative Candida NAATs except where explicitly allowed.

Broad molecular panels excluding coverage: All other tests for vaginitis (for example, broad molecular panels designed to concurrently test for vaginitis and various other STIs) not addressed above DO NOT MEET COVERAGE CRITERIA.not covered

Former CC12 now CC10 edited for clarity.

Screening of asymptomatic individuals for vaginitis pathogens is not covered. Specifically, screening asymptomatic persons — including asymptomatic pregnant individuals at average or high risk for preterm labor — for trichomoniasis or bacterial vaginosis DOES NOT MEET COVERAGE CRITERIA. Coverage of diagnostic testing is limited to patients with signs or symptoms of vaginitis and requires documentation of clinical findings (for example, discharge, odor, itch, or irritation) and relevant office tests when available. The CDC recommends that BV NAATs be used in symptomatic women only, and traditional office methods (pH, whiff/amine, wet mount microscopy, Amsel/Nugent) remain useful and lower-cost options for initial evaluation.

Broad, non-targeted molecular panels that test for a wide array of vaginal flora organisms, infertility-associated microbes, or concurrent STIs alongside vaginitis targets are not covered. Examples include multiplex panels designed to assess many organisms (such as the AMPLISwab™ and other broad commercial panels) when they are being used beyond the specific, allowed indications. The policy states that such broad molecular panels DO NOT MEET COVERAGE CRITERIA due to insufficient evidence supporting their routine use for vaginitis diagnosis.

Routine screening of pregnant persons who are asymptomatic for bacterial vaginosis is not recommended and is not covered. The USPSTF advises against screening for BV in pregnant persons who are not at increased risk for preterm delivery, and the policy mirrors this guidance. In addition, NAATs are intended for diagnostic use in symptomatic patients; NAAT-based assays should not be used for asymptomatic screening without clear clinical indication and documentation.

Multiplex vaginal NAATs (FDA-cleared platforms such as BD MAX™, Aptima BV/CV/TV, and Xpert Xpress MVP) are intended for use in patients with signs or symptoms of vaginitis and are not intended for asymptomatic screening, prognostic use, or as a test-of-cure. These multiplex assays can detect coinfections with higher sensitivity than point-of-care tests but should be used only when the patient is symptomatic and when clinical documentation supports molecular testing.

Tests not specifically addressed in the covered indications — including broad molecular panels that concurrently screen for vaginitis and a variety of other sexually transmitted infections — DO NOT MEET COVERAGE CRITERIA. When a molecular test falls outside the policy’s explicit allowed use for symptomatic vaginitis or the defined targeted assays, it should be considered non-covered.

NAAT testing for Candida that is quantitative in nature is explicitly excluded when used outside the covered indications. The policy clarifies that for all other situations not described in the allowed indications, NAAT testing for Candida (for example, quantitative NAAT testing) DOES NOT MEET COVERAGE CRITERIA. Qualitative PCR-based Candida testing, however, may meet coverage for complicated VVC as specified elsewhere in the policy.

A Pap smear alone is not a clinically useful diagnostic test for vaginitis because of its low sensitivity and specificity for vaginal infections. When Pap tests incidentally suggest vaginitis, molecular testing or confirmatory diagnostic testing (for example, microscopy, culture, or targeted NAATs in symptomatic patients) is indicated to establish the diagnosis and guide management.

The U.S. Preventive Services Task Force recommends against screening for bacterial vaginosis in pregnant persons who are not at increased risk for preterm delivery. The policy adopts this recommendation: routine screening of asymptomatic pregnant persons for BV is not recommended and is not covered in those without risk factors for preterm birth.

The revision history clarifies that quantitative NAAT testing for Candida is explicitly excluded from coverage when used in situations not otherwise described as covered. The policy therefore states that quantitative Candida NAATs DO NOT MEET COVERAGE CRITERIA unless they fall within one of the limited, specified qualifying indications (for example, qualitative PCR in complicated VVC).

Provider Responsibilities, Documentation, and Billing Guidance

Billing Rule

NAAT Panel Frequency and Retesting Interval

NAAT panel testing for vaginitis is limited to one panel per seven-day period for the same episode. Do not repeat multiplex NAAT panel testing for all three vaginitis targets (BV, VVC, Trichomonas) until a minimum treatment window has passed (minimum seven days per CDC guidance). If symptoms persist despite appropriate therapy, targeted individual organism testing may be performed within this window.

Limit: No more than one NAAT panel every 7 days for the same episode
Minimum treatment window before repeating panel testing: 7 days (per CDC/Note 1)
If symptoms persist despite treatment, individual organism testing is permissible within the 7-day window

Documentation Required

Symptomatic Indication Requirement

Multiplex vaginal NAATs and BV-specific NAATs are intended only for symptomatic patients. Routine screening of asymptomatic individuals, including asymptomatic pregnant individuals, is not covered. Document patient signs and symptoms (for example: vaginal discharge, odor, pruritus, irritation, erythema, vulvar edema) to support the medical necessity of testing.

NAATs for BV and multiplex vaginal NAATs: symptomatic women only
Screening asymptomatic individuals (including pregnant) for BV/trichomoniasis: not covered
Required: documentation of presenting signs and symptoms (e.g., discharge, odor, itch)

Documentation Required

Required Clinical Documentation and Supporting Evaluation

Clinical documentation must include a complete history and focused exam and initial office evaluation findings to justify molecular testing. Include results of pH testing, KOH 'whiff' test, saline wet mount/microscopy, and any sialidase activity testing performed. If traditional office-based tests are inconclusive, molecular assays are appropriate. Maintain records of prior diagnostic steps and treatment given when requesting repeat or additional testing.

Documentation elements: history, examination findings, vaginal pH, KOH whiff test, saline wet mount/microscopy results
Note: measurement of sialidase activity is an accepted diagnostic tool and should be documented when used
If microscopy and office tests are unavailable or inconclusive, document reason for using molecular assays

Note

Conventional Testing Before Molecular Assays

Providers should continue to use conventional office-based diagnostics (pH, KOH, wet mount microscopy, whiff test) when feasible because they are lower cost and provide rapid results; use molecular assays when these methods are unavailable, inconclusive, or when confirmation of non-albicans Candida or multiple targets is needed.

Conventional testing is useful and lower cost; molecular testing is appropriate when microscopy is not feasible or results are inconclusive
Molecular panels may improve diagnostic accuracy and reduce follow-up visits but are not a substitute for proper clinical evaluation

Documentation Required

Diagnostic Confirmation Prior to Empiric Antifungal Therapy

Diagnostic confirmation of vulvovaginal candidiasis is recommended before empiric antifungal therapy when feasible. Confirmatory testing may include visualization of yeast on wet-mount microscopy, fungal culture when microscopy is negative but suspicion remains, or PCR/culture for complicated cases to identify non-albicans Candida.

IDSA/ACOG: confirm VVC by microscopy (spores/pseudohyphae/hyphae) or culture/PCR in complicated cases prior to empiric antifungal therapy
If microscopy negative but symptoms persist, obtain culture or molecular testing to confirm diagnosis

Prior Authorization

Prior Authorization May Be Required

Prior authorization requirements may apply to certain proprietary molecular panel codes. Confirm payer-specific prior authorization rules before ordering tests listed in the applicable codes section.

Verify prior authorization for proprietary and high-complexity panel CPT/HCPCS/PLA codes (e.g., 0068U, 0330U, 0505U, 0557U and others listed in Applicable Codes)
Coverage determination may depend on member benefits and state/federal rules

Billing Rule

Coding Updates and Use of Current Codes

CPT and Proprietary Laboratory Analyses (PLA) codes for vaginitis panels are updated periodically. Use current coding when submitting claims and follow payer guidance. Healthfirst has added and removed specific codes in recent revisions; providers must use the active codes in the Applicable Codes section and confirm effective dates.

Policy revision history documents additions (e.g., 0068U, 0505U, 0557U) and removals (e.g., 87661, 87808, 0352U) — check Revision History for effective dates
Use current codes from the Applicable Codes section when billing

Denial Risk

Coding and Documentation Expectations; Denial Risk

Follow national coding, billing, and payer-specific rules. Failure to adhere to proper coding and documentation practices may result in claim denials or recoupment. This policy does not guarantee payment; reimbursement is determined by member benefits, state/federal requirements, and provider contracts.

Follow CMS, AMA CPT, HCPCS, ICD-10, NCCI, and state-specific coding/billing rules
Noncompliance with coding/documentation expectations may lead to denial or recoupment

Codes and Billing Guidance

Molecular/vaginitis panel CPT/Proprietary codesCPTCovered

81513	Infectious disease, bacterial vaginosis, quantitative real-time amplification of RNA markers for Atopobium vaginae, Gardnerella vaginalis, and Lactobacillus species, utilizing vaginal-fluid specimens, algorithm reported as a positive or negative result for bacterial vaginosis.
81514	Infectious disease, bacterial vaginosis and vaginitis, quantitative real-time amplification of DNA markers for Gardnerella vaginalis, Atopobium vaginae, Megasphaera type 1, Bacterial Vaginosis Associated Bacteria-2 (BVAB-2), and Lactobacillus species; includes separate detection of Trichomonas vaginalis and/or Candida species (C. albicans, C. tropicalis, C. parapsilosis, C. dubliniensis).
81515	Real-time PCR amplification of DNA markers for BV-associated organisms; includes separate detection of Trichomonas vaginalis and multiple Candida species, including C. glabrata/C. krusei when reported.
0068U	Candida species panel (C. albicans, C. glabrata, C. parapsilosis, C. kruseii, C tropicalis, and C. auris), amplified probe technique with qualitative report of the presence or absence of each species. Proprietary: MYCODART-PCR™ Dual Amplification Real Time PCR Panel for 6 Candida species.

Additional proprietary and ancillary procedure codesCPT | HCPCSCovered

0330U	Infectious agent detection by nucleic acid (DNA or RNA), vaginal pathogen panel, identification of 27 organisms, amplified probe technique, vaginal swab. Proprietary: Bridge Women's Health Infectious Disease Detection Test.
0505U	Infectious disease (vaginal infection), identification of 32 pathogenic organisms, swab, real-time PCR, reported as positive or negative for each organism. Proprietary: Vaginal Infection Testing (NxGen MDx LLC).
0557U	Infectious disease (bacterial vaginosis and vaginitis), real-time amplification of DNA markers for Atopobium vaginae, Gardnerella vaginalis, Megasphaera types 1 and 2, BVAB-2 and -3, Mobiluncus species, Trichomonas vaginalis, Neisseria gonorrhoeae, Candida species, Herpes simplex viruses 1 and 2, reported as detected or not detected for each organism. Proprietary: HealthTrackRx Vaginitis.
Q0111	Wet mounts, including preparations of vaginal, cervical or skin specimens.

Supportive microbiology and organism-specific codesCPTCovered

82120	Amines, vaginal fluid, qualitative.
83986	pH; body fluid, not otherwise specified.
87070	Culture, bacterial; any other source except urine, blood or stool, aerobic, with isolation and presumptive identification of isolates.
87149	Culture, typing; identification by nucleic acid (DNA or RNA) probe, direct probe technique, per culture or isolate, each organism probed.
87150	Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed.
87210	Smear, primary source with interpretation; wet mount for infectious agents (eg, saline, India ink, KOH preps).
87480	Infectious agent detection by nucleic acid (DNA or RNA); Candida species, direct probe technique.
87481	Infectious agent detection by nucleic acid (DNA or RNA); Candida species, amplified probe technique.
87482	Infectious agent detection by nucleic acid (DNA or RNA); Candida species, quantification.
87510	Infectious agent detection by nucleic acid (DNA or RNA); Gardnerella vaginalis, direct probe technique.

1–10 of 19

1/2

Policy coding changes (added/removed)CPT

0068U	CPT code added (per revision history).
0557U	CPT code added (off-cycle coding modification effective 7/1/2025).
87661	CPT code removed (per revision history).
87808	CPT code removed (per revision history).

inv-19: Vaginal pH — key diagnostic values and interpretation

Normal vaginal pH (premenopausal)4.0–4.5

Elevated pH suggesting BV>4.5

pH range suggesting trichomoniasis5.0–6.0

inv-20: NAAT repeat interval — no more than one NAAT panel test every 7 days for same episode

Maximum frequency for NAAT panel testingNo more than one NAAT panel test every 7 days for the same episode

Context for limitApplies to multiplex NAAT panels detecting VVC, BV, and/or trichomoniasis

When symptoms persistIf symptoms persist despite treatment, individual organism testing may be performed within the 7‑day window

inv-21: NAAT retest interval — minimum retest interval / treatment window guidance

Minimum retest / treatment windowAllow a minimum 7‑day treatment window (per CDC) before repeating a NAAT panel that includes organisms with longest treatment durations

RationaleThe 7‑day window reflects the longest minimum treatment course among organisms on allowed panels (eg, trichomoniasis)

Exception for persistent symptomsWhen symptoms persist despite treatment, perform targeted individual organism testing within this window as clinically indicated

Definitions and Test Descriptions

inv-39: Amsel criteria — Diagnostic criteria for BV (three of four signs)

Required findingsPresence of at least three of the following four: homogeneous thin vaginal discharge; vaginal pH >4.5; positive amine (whiff) test with 10% KOH; clue cells on wet mount

Diagnostic performanceWhen compared with Gram stain, Amsel criteria have sensitivity >90% and specificity ~77%

Use caseRecommended as a bedside diagnostic method for symptomatic BV and endorsed by ACOG

inv-40: BV definition — Shift from Lactobacillus-dominant flora to Gardnerella/anaerobes with elevated pH

DefinitionBacterial vaginosis is a shift from Lactobacillus-dominant vaginal flora to Gardnerella vaginalis and anaerobic commensals resulting in dysbiosis and elevated vaginal pH

Common featuresDecrease in hydrogen peroxide–producing Lactobacilli with overgrowth of Gardnerella and other anaerobes

Clinical relevanceThis microbial shift underlies typical BV symptoms and guides diagnostic choices (pH, Amsel/Nugent, or NAATs)

inv-41: Amsel criteria restated — Clinical diagnostic criteria requiring three of four findings

Clinical criteria (restated)Diagnosis requires at least three of: homogeneous thin discharge; vaginal pH >4.5; positive whiff test with KOH; presence of clue cells on microscopy

Role in practiceAmsel criteria remain useful for rapid, low-cost diagnosis in symptomatic patients when microscopy is available

Comparison to other testsAmsel criteria may be less costly but have variable sensitivity compared with NAATs and Gram stain (Nugent)

inv-42: Nugent score — Gram-stain–based scoring system for BV diagnosis

What it measuresGram-stain–based scoring system applied to vaginal swab samples to diagnose BV based on bacterial morphotypes

Clinical useRecommended alternative or confirmatory test to Amsel criteria for BV diagnosis (Nugent score interpretation)

Interpretation noteProvides an objective laboratory score reflecting shifts in vaginal flora rather than bedside clinical criteria

inv-43: BD MAX Vaginal Panel — Automated multiplex PCR assay detecting BV, Candida, and T. vaginalis targets

Assay typeAutomated multiplex real‑time PCR assay detecting DNA targets for BV-associated bacteria, Candida species, and Trichomonas vaginalis from vaginal swabs

Intended populationDesigned for symptomatic patients with vaginitis/vaginosis

Result formatQualitative detection reported based on targeted organism markers and algorithmic interpretation

inv-44: Aptima BV/CV/TV — NAAT assays qualitatively reporting BV, Candida species, and T. vaginalis; FDA-cleared

Assay descriptionNAAT assays (Aptima BV and Aptima CV/TV) that qualitatively report BV, Candida species, and T. vaginalis using proprietary algorithmic analysis

Regulatory statusFDA-cleared (Hologic Aptima BV and CV/TV) for detection in symptomatic patients

PerformanceClinical study reported high sensitivity and specificity for BV, Candida spp., and T. vaginalis in provider‑ and patient‑collected samples

inv-45: Amsel criteria (alternate chunk) — Clinical diagnostic criteria for BV

Amsel criteria (alternate)Presence of ≥3 of: homogeneous thin discharge; pH >4.5; positive KOH whiff; clue cells on wet mount — recommended as bedside diagnostic approach

EndorsementSupported by ACOG as a recommended diagnostic method for BV

Use limitationsMay be less sensitive in some settings compared with NAATs or Gram stain but remains rapid and low-cost

inv-46: Multiplex vaginal NAATs — Definition and intended use

DefinitionMultiplex vaginal NAATs are nucleic acid amplification tests that detect multiple vaginal pathogens (eg, BV-associated organisms, Candida spp., Trichomonas) from a single swab

Intended useIntended for diagnosis in symptomatic patients and to detect coinfections with higher sensitivity than traditional methods

Not for screeningNot intended for asymptomatic screening or as a prognostic test-of-cure

inv-47: Note 1 — CDC minimum treatment window guidance (7 days) for organisms included on allowed vaginitis panels

CDC minimum treatment window (Note 1)Per CDC, the longest minimum treatment among organisms on allowed vaginitis panels is 7 days; NAAT panels should not be repeated before this window has passed

ApplicationApplies to multiplex NAAT panels detecting BV, VVC, and trichomoniasis

Guidance on persistent symptomsIf symptoms persist after treatment, individual organism testing may be performed within the 7‑day window

inv-48: Qualitative NAAT for Candida — Qualitative testing meets criteria for complicated VVC; distinguishes from quantitative NAAT

Qualitative Candida NAAT meets coverage for complicated VVCQualitative PCR‑based identification of Candida to confirm clinical diagnosis and identify non‑albicans species MEETS COVERAGE CRITERIA for complicated vulvovaginal candidiasis

Distinction vs quantitative NAATQuantitative NAAT testing for Candida in situations not described in coverage criteria DOES NOT MEET COVERAGE CRITERIA

Clinical roleQualitative NAAT is recommended when microscopy is inconclusive or to identify non‑albicans Candida for complicated cases

Background on Vaginitis

Vaginitis denotes inflammation of the vagina most commonly caused by three conditions: bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), and trichomoniasis. Typical presenting symptoms include abnormal vaginal discharge, odor, pruritus, and vulvar irritation. Diagnosis relies on clinical evaluation and laboratory or point-of-care tests such as measurement of vaginal pH, the amine (whiff) test, and microscopy (saline wet mount and KOH preparation). NAATs and molecular panels offer improved sensitivity for certain pathogens and can detect coinfections, but their use is recommended primarily for symptomatic patients because molecular assays may detect asymptomatic colonization and are not intended for routine screening or prognostic testing.

Policy Revision History

2025-09-04revision

Reviewed and updated background, guidelines, and references; moved individual organism testing for T. vaginalis to G2157 resulting in removal of CC4, CC5, and CC10; added 'qualitative' to the Candida NAAT coverage statement (former CC6 now CC4); limited NAAT panels to no more than one test every seven days (former CC8 now CC6); added new exclusion for quantitative Candida NAAT (new CC8); edited former CC12 (now CC10) for clarity.

2025-06-04coding_update

Off-cycle coding modification: added CPT code 0557U effective 2025-07-01.

2025-04-09revision

Clarified Note 1: per CDC the longest minimum treatment for an organism on allowed vaginitis panels is seven days; NAAT panels should not be repeated before this treatment window and individual organism testing may be performed if symptoms persist.

2025-04-09coding_update

Added CPT code 0068U and removed CPT codes 87661 and 87808 as recorded in revision history.

2025-03-05revision

Updated background, guidelines and evidence base; added measurement of sialidase activity to covered diagnostic methods and removed a redundant CC for sialidase; edited multiple CCs for clarity.

2024-12-04coding_update

Off-cycle coding modification: added CPT code 81515 (effective 2025-01-01) and removed CPT code 0352U (effective 2025-01-01).

2024-09-04coding_updateLatest

Off-cycle coding modification: added CPT code 0505U (effective 2024-10-01).